Name | Value |
---|---|
Revenues | 0.0K |
Cost of Revenue | 0.0K |
Gross Profit | 0.0K |
Operating Expense | 8,588.0K |
Operating I/L | -8,588.0K |
Other Income/Expense | 383.0K |
Interest Income | 0.0K |
Pretax | -8,205.0K |
Income Tax Expense | 383.0K |
Net Income/Loss | -8,588.0K |
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development of medicine for allergic and inflammatory diseases. Their flagship product, THB001, is an oral small-molecule KIT inhibitor designed to treat chronic urticaria, a dermatologic condition characterized by mast cell activation. This innovative treatment targets red, itchy, painful welts, or hives, and also shows promise for airway and gastrointestinal tract indications.